Blue Apron reported a smaller drop in revenue than expected for the fourth quarter on Tuesday. Tonya Garcia, Retail Reporter at MarketWatch and Jason Moser, Analyst at The Motley Fool, join The Long and The Short to discuss where the meal kit delivery company goes from here.
The main focus on Blue Apron has been its customer growth. This quarter it reported a loss of 15% year-over-year in customers, reflecting a cut in marketing spend. Moser says the company's biggest issue is building up that loyal customer base with the little amount of money it has for marketing. It won't make investors feel at ease until they see some solid growth in the user category.
Plus, what sets Blue Apron apart from the others? Garcia says in this type of competitive industry each company needs to have that one thing others don't. Right now, she's not seeing anything unique about Blue Apron. She's hoping if it ramps up market spending it can figure out that key piece to the puzzle.
YouTube will offer creators a way to rejoin the streaming platform if they were banned for violating COVID-19 and election misinformation policies that are no longer in effect.
Lukas Alpert of MarketWatch explores how networks, brands, and ad buyers absorb the shockwaves when late‑night show hosts are suddenly cut — and brought back.
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
